CLINICAL TRIALS PROFILE FOR IMPAVIDO
✉ Email this page to a colleague
All Clinical Trials for Impavido
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01050907 ↗ | Miltefosine to Treat Mucocutaneous Leishmaniasis | Completed | Knight Therapeutics (USA) Inc | Phase 2 | 2010-05-01 | The purpose of this Treatment Investigational New Drug application was to make miltefosine available for mucocutaneous leishmaniasis patients presenting in the United States. If entrance criteria were met, subjects with mucosal or cutaneous leishmaniasis received miltefosine at a targeted dose of 2.5 mg/kg/day for 28 days. During treatment at weeks 1, 2, and 4, the patient returned to the treatment facility to be assessed for adverse events. Blood for transaminase and creatinine values were drawn at the midpoint and at the end of therapy. Patients returned to the treatment facility to be examined clinically at 6 weeks (ie, 2 weeks after the end of therapy), 3 months (2 months after therapy), and 7 months (6 months after treatment) for mucosal leishmaniasis and cutaneous leishmaniasis patients, and also at 13 months (12 months after treatment) for mucosal leishmaniasis patients. |
| NCT01122771 ↗ | Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 3 | 2010-05-01 | This protocol will evaluate the efficacy and safety of various combinations of the three drugs; AmBisome, Paromomycin and Miltefosine at reduced total dosage against the standard treatment with a total dose of 15mg/kg of AmBisome. |
| NCT01122771 ↗ | Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh | Completed | Shaheed Surhawardy Medical College and Hospital | Phase 3 | 2010-05-01 | This protocol will evaluate the efficacy and safety of various combinations of the three drugs; AmBisome, Paromomycin and Miltefosine at reduced total dosage against the standard treatment with a total dose of 15mg/kg of AmBisome. |
| NCT01122771 ↗ | Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh | Completed | Drugs for Neglected Diseases | Phase 3 | 2010-05-01 | This protocol will evaluate the efficacy and safety of various combinations of the three drugs; AmBisome, Paromomycin and Miltefosine at reduced total dosage against the standard treatment with a total dose of 15mg/kg of AmBisome. |
| NCT01377974 ↗ | Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis | Completed | Brasilia University Hospital | Phase 2 | 2009-07-01 | The purpose of this study is to determine whether miltefosine is effective in the treatment of mucosal leishmaniasis compared to meglumine antimoniate, the standard treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Impavido
Condition Name
Clinical Trial Locations for Impavido
Trials by Country
Clinical Trial Progress for Impavido
Clinical Trial Phase
Clinical Trial Sponsors for Impavido
Sponsor Name
